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Abstract
Purpose:  To  assess  the  short,  medium  and  long-term  results  of  bronchial  artery  embolisation
(BAE) and  identify  the  factors  favouring  the  recurrence  of  haemoptysis.
Patients  and  methods:  This  is  a  retrospective  study,  between  January  2001  and  June  2010,
comprising  53  consecutive  patients  with  BAE.  The  mean  age  was  53.8  years.  There  were  15
women (28.30%)  and  38  men  (71.69%).
Results:  The  aetiologies  of  haemoptysis  were  dominated  by  the  residual  signs  of  pulmonary
tuberculosis:  18  cases  (33.96%),  bronchial  dilations:  12  cases  (22.64%)  and  aspergilloma:  ﬁve
cases (9.43%).  The  bronchial  arteriography  showed  signs  of  bronchial  hypervascularisation  in
92.45% of  the  cases.  Forty-six  patients  had  a  ﬁrst  embolisation  (86.79%)  with  immediate  efﬁcacy
in 84.90%  of  the  cases  (n  =  45).  This  efﬁcacy  was  noted  after  more  than  3  years  in  60.08%  of  the
cases. Short  (<  30  days)  and  medium-term  (>  30  days  and  <  3  years)  recurrence  of  haemoptysis
were noted  in  17.39%  and  8.69%  of  the  cases  respectively.  A  statistically  signiﬁcant  correlation
between  aspergilloma  and  the  immediate  recurrence  was  found  (P  =  0.013).  The  risk  of  medium
and long-term  recurrence  (>  3  years)  was  correlated  with  age.  The  survival  without  recurrence
was statistically  higher  when  the  age  was  less  than  60  years  (P  =  0.0041).
Conclusion:  BAE  is  an  effective  treatment.  Aspergilloma  is  a  major  risk  factor  in  the  recurrence
of haemoptysis.  Repeated  embolisation  may  be  proposed  for  these  patients.
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Boxed  text  1  Signs  of  bronchial
hypervascularisation  in  the  bronchial  arteriography.
• Hypertrophy  of  the  arterial  branch:  this  may  occur  by
an  increase  in  the  diameter  of  the  artery,  a  twisted
appearance  or  excessively  good  distal  visualisation.
• An  excessive  parenchymograph  or  parenchymatous
blush  attesting  to  hypervascularisation.
• A  systemo-pulmonary  or  systemo-systemic  shunt.
•
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Haemoptysis  accounts  for  10  to  15%  of  all  admissions  in
pneumology  [1].  It  requires  emergency  care  in  a  specialised
environment.  In  fact,  in  spite  of  this  care,  death  due  to
major  haemoptysis  ranges  from  50  to  100%  even  after  surgi-
cal  haemostasis  [2,3]. Bronchial  artery  embolisation  (BAE),
ﬁrst  described  by  J.  Rémy  in  1973,  achieves  emergency
haemostasis  by  reducing  systemic  hypervascularisation  [4].
Interventional  radiology  is  currently  an  alternative  treat-
ment  to  control  haemoptysis.  In  fact,  BAE  is  the  only
treatment  for  inoperable  patients.  In  most  cases,  BAE  can
immediately  control  the  haemoptysis  although  medium  and
long-term  recurrences  may  occur.  The  purpose  of  this  paper
is  to  assess  the  short,  medium  and  long-term  results  of  BAE
and  identify  the  factors  favouring  the  recurrence  of  haemop-
tysis,  especially  in  our  country,  still  a  country  with  endemic
tuberculosis.
Patients and methods
This  retrospective  study,  carried  out  from  January  2001
to  June  2010,  included  53  patients  referred  by  different
pneumology  departments  in  Greater  Tunis.  All  of  the  BAE
were  carried  out  by  the  same  radiologist,  in  the  interven-
tional  radiology  unit  at  Hôpital  Charles-Nicolle  in  Tunisia,
equipped  with  a  digital  angiograph  (Philips  Integris  V  3000)
comprising  of  a  rotary  arc.  The  haemoptysis  was  consid-
ered  to  be  mild  if  under  100  mL/24  h,  moderate  if  between
100  and  400  mL/24  h  and  major  if  over  400  mL/24  h.  All
of  the  patients  beneﬁted  from  bronchial  ﬁbroscopy  and  a
chest  CT  with  injection  of  contrast  product  in  order  to
determine  the  source  of  the  bleeding  as  well  as  the  under-
lying  disease.  Thirty-six  patients  had  a  single-slice  spiral  CT
(67.92%)  and  17  patients  (32.07%)  had  a  multi-slice  thoracic
angio-CT  (ATMC)  (16  slices).  The  ATMC  protocol  included  the
acquisition  at  aortic  time  with  an  output  of  4  mL/s.  The
acquisition  was  16  ×  1.25  mm  with  an  interval  of  0.625  min
followed  by  vascular  MIP,  MPR  and  curvilinear  reconstruc-
tions.
The  embolisation  was  carried  out  under  local  anaes-
thetic.  The  arterial  approach  involved  a  puncture  of  the
right  common  femoral  artery,  followed  by  the  placement
of  a  5-French  introducer  according  to  the  Seldinger  tech-
nique.  The  arteriography  prior  to  the  embolisation  was
carried  out  using  a  5-French  Pigtail  catheter.  The  selec-
tive  catheterisation  of  the  bronchial  arteries  was  carried  out
with  a  5-French  Cobra  catheter  and  a  Terumo® hydrophilic
guidewire.  In  certain  cases,  hyper-selective  catheterisa-
tion  was  necessary  with  a  3F  micro-catheter  assembled
through  a  catheter  guide.  At  the  end  of  the  diagnos-
tic  stage,  a  decision  for  embolisation  was  made  on  the
basis  of  the  signs  indicating  systemic  bronchial  or  non-
bronchial  hypervascularisation  (Boxed  text  1),  or  oriented
by  thoracic  angio-CT  specifying  the  topography  and/or  the
cause  of  the  bleeding.  The  angiograph  is  used  to  detect
the  anterior  spinal  artery  that  requires  special  care.  This
was  identiﬁed  in  only  one  of  our  patients,  since  hyper-
selective  catheterisation  beyond  the  origin  of  the  spinal
artery  was  technically  difﬁcult  in  this  case.  The  embolic
agent  was  chosen  according  to  the  vascular  lesion  and  the
availability  of  the  vascular  occlusion  agent.  We  used  three
types:
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c• Aneurisms,  or  extravasation  of  contrast  product  in
the  bronchial  lumen.
gelatine  (Curaspon® or  Spongel®)  that  are  solid
absorbable  particles;
embospheres  that  are  500  to  1200  m  solid  non-
absorbable  particles;
metal  spires  (or  coils).
The  results  were  immediately  estimated  after  the  arte-
iography,  on  a  short-term  basis  until  30  days  after  the
mbolisation,  on  a  medium-term  basis  (>  1  month  and  <  3
ears)  and  on  a  long-term  basis  (≥  to  3  years).  For  the  statis-
ical  study,  the  means  were  compared  using  Student’s  t-test
nd  the  percentages  with  Pearson’s  Chi2 test  or  Fisher’s
xact  test.  A  single  and  multivariate  study  was  used  to  cal-
ulate  the  factors  of  risk.
esults
he  mean  age  of  the  patients  was  53.8  years  (20  to  79  years).
here  were  15  women  (28.30%)  and  38  men  (71.69%).  Only
ne  patient  suffered  from  mild  haemoptysis  although  it  was
ecurrent.  The  haemoptysis  was  moderate  in  41  patients
77.35%  of  the  cases)  and  major  in  11  patients  (20.75%  of
he  cases).  The  aetiologies  of  the  haemoptysis  are  presented
n  Table  1.  They  are  dominated  by  the  residual  signs  of
ulmonary  tuberculosis:  18  cases  (33.96%),  bronchial  dila-
ion:  12  cases  (22.64%)  and  aspergilloma:  ﬁve  cases  (9.43%).
he  thoracic  tomodensitometry  detected  unpolished  glass
mages  in  10  cases  (18.86%)  and  parenchymatous  condensa-
ion  in  12  cases  (22.64%),  attesting  to  local  bleeding  in  the
ulmonary  parenchyma  and  signs  related  to  the  underlying
isease  in  17  cases  (32.07%).
Study  of  the  systemic  and  non-systemic  arterial  vas-
ularisation  was  inadequate  by  the  single-slice  CT.  In  the
7  patients  with  ATMC,  we  detected  hypertrophic  and
ilated  bronchial  and  non-bronchial  systemic  arteries  in
4  cases  (82.35%)  (Fig.  1).  The  thoracic  CT  helped  deter-
ine  the  cause  of  the  haemoptysis  in  92%  of  the  cases.
t  was  not  helpful  in  ﬁve  patients  (9%).  In  these  patients,
he  arteriography  revealed  the  existence  of  a  parenchy-
atous  blush  and  hypertrophy  of  an  arterial  segment  in
our  patients.  The  bronchial  arteriography  revealed  signs
f  bronchial  hypervascularisation  in  49  patients  (92.45%
f  the  cases).  The  association  of  arterial  hypertrophy  and
arenchymatous  blush  was  noted  in  41  patients  (77.35%).
solated  parenchymatous  blush  was  found  in  eight  cases
15.09%).  Systemo-pulmonary  shunting  was  observed  in
our  cases  (7.54%),  in  all  cases  consisting  of  counter-
urrent  shunting.  Associated  extravasation  of  the  contrast
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Table  1  Aetiologies  of  haemoptysis.
Aetiology  Number  of  patients  Percentage
Residual  signs  of  pulmonary  tuberculosis 18  33.96
Bronchial  dilation  12  22.64
Non-operable  bronchopulmonary  cancer  5  9.43
Aspergilloma 5  9.43
Active  pulmonary  tuberculosis 5 9.43
Non-speciﬁc  infectious  pneumopathy 3 5.66
Arteriovenous  malformation 1 1.88
Bronchogenic  cyst  1  1.88
Idiopathic  3  5.66
Figure 1. Major haemoptysis in a 52-year-old man with a past history of pulmonary tuberculosis. a: thoracic CT scan. The right upper
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pobe is destroyed with right intercostal systemic hypervascularisat
he fourth right intercostal artery.
roduct  was  described  in  two  cases  (3.77%).  The  arte-
iography  was  normal  in  four  patients.  One  patient  had
ilation  lesions  of  the  cylindrical  segmental  bronchi,  two
atients  had  residual  signs  of  minor  localised  tuberculo-
is  and  one  patient  had  primary  bronchopulmonary  cancer.
he  haemoptysis  was  moderate  in  these  four  cases.  On
he  anatomic  level,  64  arteries  were  responsible  for
he  haemoptysis.  In  decreasing  order  of  occurrence  they
nvolved:
the  right  bronchial  artery  in  30.18%  of  the  cases  (16
patients);
the  left  bronchial  artery  in  28.30%  of  the  cases  (15
patients);
the  non-bronchial  systemic  arteries  in  24.52%  of  the
cases  (13  patients):  the  intercostal  arteries  in  12  patients
(Fig.  2)  and  a  collateral  branch  of  the  left  scapular  artery
(Fig.  3),  the  thyro-bicervico-scapular  trunk  in  another
patient  (Fig.  4);
the  right  broncho-intercostal  trunk  in  18.86%  of  the  cases
(10  patients);
the  right-left  common  trunk  in  16.98%  of  the  cases  (nine
patients);
one  patient  had  a  left  superior  bronchial  artery  that  arose
from  the  left  internal  mammary  artery  (Fig.  5).
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prrow); b: the selective arteriography conﬁrms the hypertrophy of
Forty-six  patients  had  a ﬁrst  embolisation  (86.79%).  Six
f  them  had  two  embolisations  and  one  had  three  embolisa-
ions.  Our  statistical  study  only  took  the  ﬁrst  embolisation
nto  account.  Complete  stagnation  of  the  contrast  prod-
ct  was  obtained  in  45  of  the  46  patients  that  had  a  ﬁrst
mbolisation  (84.90%).  We  noted  eight  failures  (15.09%)  in
mbolisation.  In  one  case,  the  bleeding  did  not  completely
top  with  incomplete  stagnation  of  the  contrast  product.
he  failure  was  technical  in  the  seven  other  cases  (13%):
four  patients  had  a  normal  arteriography;
one  patient,  in  whom  we  detected  an  anterior  spinal
artery  arising  form  the  TBICD,  required  surgery  (right
superior  lobectomy  for  dilation  of  the  bronchi);
in  two  cases,  the  failure  was  due  to  the  impossibility
of  catheterisation  of  the  bronchial  artery  responsible  for
the  bleeding.  One  patient  required  surgery  and  another
evolved  well  with  medical  treatment.
The  ﬁrst  embolisation  was  carried  out  with  Curaspon®
articles  in  38  cases  (82.60%  of  the  cases),  embospheres  in
ix  cases  (13.04%  of  the  cases),  the  association  of  embo-
pheres  and  coil  in  one  case  and  Curaspon® and  coils  in  one
ase.  A  micro-catheter  was  used  in  30.43%  of  the  cases  (14
atients).  Only  one  complication  was  noted:  it  consisted  of
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Figure 2. Major haemoptysis in a 50-year-old man  with a past
history of tuberculosis. Global aortography revealing hypertrophy
of the fourth right intercostal artery (arrow) and the right broncho-
intercostal trunk (head of arrow).
Figure 3. Recurrent haemoptysis in a 65-year-old man with a
past history of pulmonary tuberculosis. Selective catheterisation of
the left subclavian artery revealing a collateral branch of the left
Figure 4. Systemic hypervascularisation of the right pulmonary
apex fed by the branches arising from the right thyro-bicervico-
scapular trunk (arrow).
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evolution  after  the  recurrence  of  the  haemoptysis  isscapular artery feeding a vascular blush (arrow).
left  brain  ischemia  forming  7  days  after  embolisation  in  a
65-year-old  smoker.  In  view  of  this  delay,  it  is  not  certain
that  it  may  be  attributed  to  the  endovascular  procedure.  A
long-term  recurrence  was  not  noted  in  28  of  the  46  patients
beneﬁting  from  embolisation  (60.08%)  after  more  than  3
years.  Four  patients  dropped-out  10,  12,  18  and  20  months
after  the  embolisation  without  a  recurrence  of  the  haemop-
tysis  during  this  period.  Two  patients  died  after  12  and  18
d
tigure 5. Origin of the upper left bronchial artery from the left
nternal mammary artery with transpleural route (arrows).
onths  from  the  underlying  disease.  Twelve  patients  pre-
ented  a  recurrence  of  haemoptysis:
eight  patients  (17.39%)  who  had  a  short-term  recurrence
of  the  haemoptysis  (≤  1  month),  including  one  death
10  hours  after  the  embolisation  in  a  picture  of  severe
respiratory  failure  by  alveolar  ﬂooding.  Half  of  these  early
recurrences  occurred  in  patients  presenting  aspergilloma;
four  patients  (8.69%)  had  a  medium-term  recurrence.
The  results  of  the  embolisation  according  to  the  aeti-
logy  of  the  haemoptysis  are  reported  in  Table  2.  Theetailed  in  Table  3.  There  is  a  statistically  signiﬁcant  rela-
ionship  between  aspergilloma  and  short-term  recurrence
42  H.  Racil  et  al.
Table  2  Result  of  the  embolisation  according  to  the  underlying  disease.
Underlying  disease  BAE
(n  =  46)
No  recurrence
(n =  34)a (%)
Recurrence
(n  =  12)  (%)
P  value
Residual  signs  of  tuberculosis  (excluding  aspegilloma  graft) 16  13  (81.25)  3  (18.7)  0.3
Bronchial  dilation  8  8  (100)  0  0.07
Non-operable  bronchopulmonary  cancer  4  3  (75)  1  (25)  0.7
Aspergilloma 5  1  (20)  4  (80)  0.013
Active  pulmonary  tuberculosis 5 4 (80)  1  (20) 0.6
Non-speciﬁc  infectious  pneumopathy 3 2 (66.67)  1  (33.34) 0.6
Arteriovenous  malformation 1 1 (100)  0 0.7
Bronchogenic  cyst  1  100  0.2
Idiopathic  3  2  (66.67)  1  (33.34)  0.6
BAE: bronchial artery embolisation.
a Including four drop-outs between 10 and 20 months and two deaths at 12 and 18 months.
Table  3  Evolution  after  ﬁrst  recurrence  of  the  haemoptysis.
Diagnosis  n  =  12  Date  of
recurrence
Treatment  of  the
recurrence
Evolution
Residual  signs  of  tuberculosis  1st  patient  D4
D  2  years  after
2nd  BAE
2nd  BAE  (D4)
3rd  BAE
No recurrence
2nd  patient  D  2  months  2nd  BAE  No  recurrence
3rd  patient  D  12  months  Surgery  No  recurrence
Bronchopulmonary  cancer  1  patient  D2  Medical  treatment  Died  on  D10  due
to neoplastic
disease
Aspergilloma  1st  patient  D0  —  Died  by
haemoptysis
2nd  patient  D9
D8  after  2nd  BAE
2nd  embolisation
surgery
No  recurrence
3rd  patient  D18  2nd  embolisation  No  recurrence
4th  patient  D30  2nd  embolisation  Recurrence  of
haemoptysis
Active  pulmonary  tuberculosis  1  patient  D  2  months  2nd  embolisation  No  recurrence
Infectious  pneumopathy 1  patient  D2  Surgery  No  recurrence
Bronchogenic  cyst  1  patient  D30  Surgery  No  recurrence
Idiopathic  1  patient  D  13  months  2nd  embolisation  No  recurrence
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P  =  0.013).  We  calculated  the  cumulate  survival  without
ecurrence  using  the  Kaplan-Meier  method  in  the  patients
hat  did  not  have  a  recurrence  more  than  30  days  after  the
mbolisation.  The  mean  survival  without  recurrence  is  43
onths.  The  risk  of  medium  and  long-term  recurrence  was
ultiplied  by  8.2  when  the  age  was  more  than  or  equal  to  60
ears.  There  is  a  signiﬁcant  difference  in  the  survival  curves
ithout  recurrence  (P  =  0.0041).  The  survival  without  recur-
ence  was  statistically  better  when  the  age  was  less  than  60
ears  (Fig.  6).iscussion
he  treatment  of  haemoptysis,  in  particular  by  BAE,  depends
n  the  aetiology,  abundance  and  tolerance.  The  aetiologies
Figure 6. Cumulate survival curves without recurrence as a func-
tion of age.
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of  haemoptysis  are  numerous  in  the  series  by  Cremaschi
[5],  Zhang  [6]  and  Karen  [7].  Bronchial  dilation  is  the
leading  cause  of  haemoptysis,  followed  by  tuberculosis.  Nev-
ertheless,  in  our  series,  tuberculosis  is  the  leading  cause
of  haemoptysis,  given  that  tuberculosis  is  still  endemic  in
Tunisia.
Certain  complementary  examinations  are  indispensable
when  faced  with  haemoptysis.  The  association  of  bronchial
ﬁbroscopy  and  ATMC,  in  most  cases,  provides  a  topographic
diagnosis  and  the  aetiology  of  the  haemoptysis  [8,9]. How-
ever,  the  role  of  bronchial  ﬁbroscopy  is  currently  highly
debated,  in  particular  since  the  arrival  of  the  multi-slice
angio-CT  (ATMC).  The  ATMC  provides  a  pulmonary  vascu-
lar  map  as  well  as  an  exhaustive  study  of  the  mediastinum
and  the  parenchyma  during  the  same  acquisition  [10]. The
ATMC  identiﬁes  all  of  the  catheterisable  bronchial  arter-
ies  in  angiography  that  are  the  source  of  the  bleeding,  as
well  as  detects  pulmonary  arterial  anomalies  and  therefore,
avoids  useless  bronchial  angiographies  and  correctly  indi-
cates  the  therapeutic  attitude  [11,12].  Nevertheless,  the
ATMC  does  not  identify  certain  collateral  bronchial  arter-
ies,  in  particular  the  anterior  median  spinal  artery.  Only  the
anterior  lumbar  spinal  artery  can  be  detected  at  this  time
[12].  In  our  series,  the  ATMC  detects  the  dilated  bronchial
and  non-bronchial  systemic  arteries,  attesting  to  hypervas-
cularisation  in  82.35%  of  the  cases.  However,  it  is  difﬁcult  to
determine  reliable  criteria,  through  an  analysis  of  the  liter-
ature,  in  order  to  assess  the  efﬁcacy  of  embolisation.  There
are  two  reasons  for  this:
• on the  one  hand,  the  heterogeneity  of  the  different  series
in  the  literature  in  terms  of  abundance  of  the  haemopty-
sis,  does  not  always  allow  for  reliable  comparison;
• on  the  other  hand,  the  criteria  selected  in  the  differ-
ent  series  in  the  literature  vary:  immediate  arrest  of
the  haemoptysis  (active  haemoptysis),  a  satisfactory  post-
embolisation  arteriographic  aspect,  or  even  the  absence
of  short  and  long-term  recurrence.  This  most  often
accounts  for  the  difﬁculty  in  data  gathering.
In  our  series,  the  immediate  efﬁcacy  was  84.90%.  Our
results  are  similar  to  those  presented  in  the  literature.
In  fact,  a  very  high  immediate  efﬁcacy  has  always  been
reported  in  the  different  series,  oscillating  between  73%
and  99%  [13—19]. BAE  is  an  effective  procedure  to  stabilise
many  patients  and  deﬁnitively  treat  others  [7,10]. Never-
theless,  its  short-term  efﬁcacy  (<  30  days)  is  reported  less
often.  Several  studies  have  reported  a  risk  of  recurrence
ranging  from  10  to  29%  during  the  ﬁrst  month  after  emboli-
sation  [14,16,19]. In  our  series,  the  short-term  recurrence
was  noted  in  15.21%  of  the  cases.
The  short-term  recurrence  depends  on  the  aetiology.  A
favourable  evolution  was  noted  in  case  of  active  pulmonary
tuberculosis  after  antitubercular  therapy  and  embolisation
with  a  high  rate  of  immediate  success  and  a  low  rate  of
recurrence  [19,20].  An  unfavourable  prognosis  was  noted
in  patients  presenting  aspergilloma  [17,19,21—24]. A  recent
study  reports  a  recurrence  in  100%  of  the  cases  in  these
patients.  Most  of  the  recurrences  occur  within  2  weeks
after  embolisation  with  a  mortality  of  up  to  50%  during  the
ﬁrst  month  [19]. Aspergilloma  is  therefore  correlated  with  a
statistically  signiﬁcant  risk  of  haemoptoic  recurrence  bothassessment  43
n  the  literature  and  in  our  series  [23]  requiring  repeated
mbolisation  at  best  associated  with  surgery.
In  our  series,  50%  of  the  short-term  recurrences  were
elated  to  aspergilloma  and  80%  of  the  patients  with
spergilloma  presented  a short-term  recurrence.  Neoplastic
ulmonary  disease  is  also  the  cause  of  the  immediate  and
ong-term  recurrence  of  haemoptysis  (which  was  not  found
n  our  series)  and  is  associated  with  a  mortality  related  to
he  progressive  nature  of  the  underlying  disease  [15,17].
he  long-term  recurrence  of  haemoptysis  is  secondary  to
e-canalisation  of  the  previously  embolised  vessel  or  the
evascularisation  of  the  collaterals  as  related  to  the  pro-
ression  of  the  underlying  pulmonary  disease,  in  particular
spergilloma  [14,15,19,20]. This  recurrence  may  occur  after
 period  of  2  to  5  years  [19,20].  Therefore,  it  is  important
o  identify  and  embolise  all  vessels  that  may  contribute  to
n  abnormal  vascular  replacement.  Repeated  embolisations
ay  thereby  help  improve  the  prognosis  in  case  of  the  recur-
ence  of  haemoptysis  after  a  ﬁrst  embolisation.  A  second
mbolisation  was  carried  out  in  seven  patients,  including
hree  for  aspergilloma  graft.  One  patient  had  BAE  on  three
ccasions.
In  our  study,  we  noted  that  age  may  also  be  a  factor  in
he  prognosis.
In  addition  to  predisposition-related  factors,  the  efﬁcacy
f  embolisation  also  depends  on  the  material  used.  Gelatine
s  cheap,  easy  to  use  and  the  size  of  the  particles  can  be
ontrolled.  However,  due  to  its  non-absorbable  nature,  cer-
ain  authors  think  that  it  may  foster  medium  and  long-term
ecurrence  [15,25].  In  our  study,  gelatine  seems  to  be  as
ffective  as  the  other  embolisation  agents.  In  fact,  the  dif-
erence  in  the  cumulate  survival  without  recurrence  in  the
atients  treated  with  Curaspon® and  in  those  treated  with
mphospheres  is  not  statistically  signiﬁcant.  A  recent  study
as  demonstrated  the  possibility  of  using  the  ethylene-vinyl
lcohol  copolymer,  which  seems  to  be  beneﬁcial  in  patients
resenting  recurrent  haemoptysis  [26].
onclusion
ur  study  conﬁrms  the  safety  and  value  of  BAE  in  the  treat-
ent  of  haemoptysis.  The  nature  of  the  underlying  disease
nd  the  underlying  predisposition,  in  particular  age,  are
mportant  factors  to  take  into  account  in  the  therapeutic
ecision.  We  noted  that  aspergilloma  is  the  major  factor  of
isk  at  the  origin  of  haemoptoic  recurrences  after  emboli-
ation.  Another  embolisation  may  be  proposed  for  these
atients.
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